Adverse events35

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 35

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Neutrophil count decreased	Immune system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	24	34	24
other	Fatigue	Respiratory, thoracic and mediastinal disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	20	34	20
other	Platelet count decreased	Blood and lymphatic system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	17	34	17
other	Anaemia	Blood and lymphatic system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	8	34	8
other	Diarrhoea	Gastrointestinal disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	7	34	7
other	Nausea	Gastrointestinal disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	6	34	6
other	Cognitive disturbance	Nervous system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	5	34	5
other	Seizure	Nervous system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	4	34	4
other	Flu like symptoms	General disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	5	34	5
other	Dyspepsia	Gastrointestinal disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	5	34	5
other	Cephalea	Nervous system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	5	34	5
other	Pruritus	Skin and subcutaneous tissue disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	4	34	4
other	Vomiting	Gastrointestinal disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	3	34	3
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	3	34	3
other	Fever	General disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	3	34	3
other	Epistaxis	Respiratory, thoracic and mediastinal disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	3	34	3
other	Dizziness	Nervous system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	3	34	3
other	Confusion	Psychiatric disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	2	34	2
other	Cognitive impairment	Nervous system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	2	34	2
other	White blood cell decreased	Blood and lymphatic system disorders	Patients With Recurrent Anaplastic (Grade III) Oligodendrogliomas.	2	34	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02530320/events

API reference For AI assistants

Adverse events35

Sources 3

Read this list from software.